Abstract:1545 Purpose: To investigate the in vivo imaging characteristics of a novel tau tracer ((S)-1-(4-(6-(dimethylamino) naphthalen-2-yl)phenoxy)-3-fluoropropan-2-ol,18F-S16) in humans and evaluate its performance in identifying AD patients from healthy controls (HCs) as compared with 18F-THK5317. Methods: The study cohort consisted of 6 AD, 1 FTLD, 1 PSP, 1 DLB, 6 HCs and 2 young volunteers. While dynamic PET was performed over a period of 90 min after injection in 1 AD, 6 HCs and 2 young volunteers, static images were acquired in all subjects from 40 min to 60 min after tracers’ administration. All PET data were co-registered to the corresponding MRI data. The time-activity curves of standardized uptake value (SUV) and SUV ratios (SUVRs) were extracted from regions of interested based on the AAL atlas. Logan graphical analysis was performed for quantification of distribution volume ratios (DVRs). Cerebellum was used as the reference region to calculate DVRs and SUVRs. SUVRs derived from 70-90 min and 40-60min were regressed onto DVR to assess the quantitative accuracy of SUVR. Two-sample t-test was performed for the voxel-based analyses of both tracers to assess their uptake differences between populations. Results: Both tracers were distributed to the brain rapidly but the clearance of 18F-S16 was slower than 18F-THK5317 at 90 min acquisition. The AD patient showed increased cortical 18F-S16 binding (e.g., the medial temporal cortex), which was in contrast to a minimal accumulation of tracers seen in the young volunteers. Regional SUVR of both tracers’ time courses showed differences between groups in medial temporal cortex, lateral temporal cortex and occipital cortex. But the SUVR of 18F-S16 was still increasing at 90 min in very high-binding regions. Regression outcome of SUVR70-90min onto DVR performed better than SUVR40-60min. As to images, 18F-S16 displayed higher grey matter but lower white matter uptake than 18F-THK5317 in controls. In comparative studies, the cortical average SUVR of 18F-THK5317 was 1.32 ± 0.10 for AD versus 1.15 ± 0.05 for HCs (F = 5.91, P < 0.05), and for 18F-S16, that was 1.20 ± 0.08 versus 1.14 ± 0.06, respectively (F = 3.17, P < 0.05) (Table 1.). In voxelwised analysis, AD patients showed significant increased cortical 18F-THK5317 binding in diffused bilateral cortical regions; 18F-S16 displayed increased abnormal radioactive retention in bilateral lateral temporal cortex, occipital cortex and right frontal cortex (Figure 1.). The patterns of uptake of both tracers were similar in FLTD and PSP patients, which were observed increased radioactive retention in the anterior temporal cortex, the globus pallidus and midbrain, respectively. No obvious abnormal uptake was found in the DLB patient. Conclusions: A significant difference in 18F-S16 uptake between AD and HCs in cortical regions especially from 40-60 min after the tracer administration and elevated 18F-S16 retention was observed in where tau pathology frequently occurred in patients with PSP, thus 18F-S16 might be a promising tau-tracer for PET imaging. But quantification strategies for 18F-S16 need to be well evaluated with longer scan duration, such as 180min, in view of its slower clearance from brain.

Measurement of Cerebral Perfusion Indices from the Early Phase of [18F]MK6240 Dynamic Tau PET Imaging

Assessment of perfusion deficit with early phases of [18F]PI-2620 tau-PET versus [18F]flutemetamol-amyloid-PET recordings

Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease

Kinetic modeling of 18F-PI-2620 binding in the brain using an image-derived input function with total-body PET

Reproducibility of [18F]MK-6240 kinetics in brain studies with shortened dynamic PET protocol in healthy/cognitively normal subjects

Clinical evaluation of [18F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease

Study Of Tau Deposition In Patients Of Alzheimer'S Disease With [F-18]-Apn-1607 Pet Tracer And Its Relationship With Cerebral Glucose Metabolism

Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment

Kinetic modeling of the monoamine oxidase-B radioligand [18F]SMBT-1 in human brain with positron emission tomography

Kinetic Analysis of Cardiac Dynamic 18F-Florbetapir PET in Healthy Volunteers and Amyloidosis Patients: A Pilot Study

In Vivo Imaging of Neurofibrillary Tau PET Radioligand 18F-S16 in Comparison with 18F-THK5317 in Alzheimer's Disease

Associations of [18F]-APN-1607 Tau PET Binding in the Brain of Alzheimer’s Disease Patients With Cognition and Glucose Metabolism

The Early Perfusion Image Is Useful to Support the Visual Interpretation of Brain Amyloid-PET With 18F-Flutemetamol in Borderline Cases

Simultaneous phase-contrast MRI and PET for noninvasive quantification of cerebral blood flow and reactivity in healthy subjects and patients with cerebrovascular disease

IN VIVO MAPPING OF TAU DEPOSITION, PERFUSION, AND CORTICAL THINNING IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE

Abstract TP89: Absolute Cerebral Blood Flow Assessment With Novel Low-Dose Whole Brain Dynamic CT Perfusion Technique

Noninvasive Quantification of the Cerebral Metabolic Rate for Glucose Using Positron Emission Tomography,18F-Fluoro-2-Deoxyglucose, the Patlak Method, and an Image-Derived Input Function

Imaging of Brain Hypoxia in Permanent and Temporary Middle Cerebral Artery Occlusion in the Rat Using 18F-Fluoromisonidazole and Positron Emission Tomography: A Pilot Study

Combining cerebrospinal fluid and PI‐2620 tau‐PET for biomarker‐based stratification of Alzheimer's disease and 4R‐tauopathies

The cellular basis of increased PET hypoxia tracer uptake in focal cerebral ischemia with comparison between [<SUP>18</SUP>F]FMISO and [<SUP>64</SUP>Cu]CuATSM

Identifying Mild Alzheimer's Disease With First 30-Min 11C-PiB PET Scan